News: Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

53.26USD
21 Oct 2014
Price Change (% chg)

$1.57 (+3.04%)
Prev Close
$51.69
Open
$52.14
Day's High
$53.29
Day's Low
$51.73
Volume
686,335
Avg. Vol
608,816
52-wk High
$55.70
52-wk Low
$36.26

Search Stocks
Select another date:

Wed, Oct 15 2014

UPDATE 2-U.S. top court divided in battle over Teva MS drug patent

(Adds fresh details from oral argument, paragraphs 8-9, 11-12)

U.S. Supreme Court justices divided over Teva patent battle

WASHINGTON, Oct 15 - The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug.

U.S. top court hears Teva's multiple sclerosis drug patent fight

WASHINGTON - The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term.

U.S. top court hears Teva's multiple sclerosis drug patent fight

WASHINGTON, Oct 15 - The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term.

Actavis to buy Durata in a deal valued at about $675 million

- Generic drugmaker Actavis Plc said it would acquire Durata Therapeutics Inc in a deal valued at about $675 million to bolster its infectious disease portfolio.

UPDATE 1-Actavis to buy Durata in a deal valued at about $675 mln

Oct 6 - Generic drugmaker Actavis Plc said it would acquire Durata Therapeutics Inc in a deal valued at about $675 million to bolster its infectious disease portfolio.

Teva Pharm to halt R&D in cancer and women's health to cut costs

TEL AVIV - Teva Pharmaceutical Industries said it will stop research and development in areas such as oncology and women's health to cut costs, though it will maintain a commercial presence in these areas.

Teva Pharm to halt R&D in cancer and women's health to cut costs

TEL AVIV, Oct 6 - Teva Pharmaceutical Industries said it will stop research and development in areas such as oncology and women's health to cut costs, though it will maintain a commercial presence in these areas.

Gay marriage aside, business cases dominate U.S. high court docket

WASHINGTON - Gay marriage may be the most anticipated issue heading for the U.S. Supreme Court, but the justices also must tackle a host of business cases as they convene for their new term, including a patent battle involving Teva Pharmaceutical Industries Ltd.

CORRECTED-BRIEF-Teva Pharmaceutical present new data on MS drug Copaxone

(Corrects company name in headline to Teva Pharmaceutical from Teva Pharmaceuticals. Also, removes incorrect reference to Copaxone as an experimental MS drug)

Select another date:

Press Releases

Search Stocks